- Home
- SQNS vs AVTX Comparison
SQNS vs AVTX Comparison
Compare SQNS & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQNS
- AVTX
- Stock Information
- Founded
- SQNS 2003
- AVTX 2011
- Country
- SQNS France
- AVTX United States
- Employees
- SQNS N/A
- AVTX N/A
- Industry
- SQNS Semiconductors
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- SQNS Technology
- AVTX Health Care
- Exchange
- SQNS Nasdaq
- AVTX Nasdaq
- Market Cap
- SQNS 147.0M
- AVTX 138.8M
- IPO Year
- SQNS 2011
- AVTX 2015
- Fundamental
- Price
- SQNS $0.96
- AVTX $10.14
- Analyst Decision
- SQNS Buy
- AVTX Strong Buy
- Analyst Count
- SQNS 1
- AVTX 8
- Target Price
- SQNS $3.50
- AVTX $31.00
- AVG Volume (30 Days)
- SQNS 4.2M
- AVTX 168.1K
- Earning Date
- SQNS 11-04-2025
- AVTX 11-06-2025
- Dividend Yield
- SQNS N/A
- AVTX N/A
- EPS Growth
- SQNS N/A
- AVTX N/A
- EPS
- SQNS 1.85
- AVTX N/A
- Revenue
- SQNS $37,325,000.00
- AVTX $441,000.00
- Revenue This Year
- SQNS N/A
- AVTX N/A
- Revenue Next Year
- SQNS $63.27
- AVTX N/A
- P/E Ratio
- SQNS $0.54
- AVTX N/A
- Revenue Growth
- SQNS 32.07
- AVTX N/A
- 52 Week Low
- SQNS $0.73
- AVTX $3.39
- 52 Week High
- SQNS $5.83
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- SQNS 41.48
- AVTX 54.75
- Support Level
- SQNS $0.93
- AVTX $8.65
- Resistance Level
- SQNS $1.00
- AVTX $12.41
- Average True Range (ATR)
- SQNS 0.07
- AVTX 0.92
- MACD
- SQNS 0.05
- AVTX -0.08
- Stochastic Oscillator
- SQNS 85.85
- AVTX 39.63
About SQNS Sequans Communications S.A.
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).